The Genetics of Pulmonary Fibrosis
Part of paid clinical trials in Aurora, Colorado.
- Sponsor
- University of Colorado, Denver
- Study ID
- NCT03478553
- Status
- Recruiting
Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Accepted
Interventions
- Blood draw — OTHERBlood draw
- Questionnaire — OTHERPulmonary Fibrosis Questionnaire
Study Details
This study seeks to screen first degree family members of people with Idiopathic Pulmonary Fibrosis (IPF) for the earliest signs of lung fibrosis.
Key Dates
- Start date
- Jan 18, 2018
- Status verified
- Mar 2025
- Primary completion
- Dec 31, 2026
- Completion
- Dec 31, 2026
Study Design
- Enrollment
- 1,000 participants (estimated)
Arms
- Arm: People with IPF
- Arm: Family members without IPF
Primary Outcome Measure
Identify and explore genetic loci and related environmental exposures in individuals with familial pulmonary fibrosis and their relatives. [ Time Frame: Baseline ]
Central Contacts
- Rachel Warren303-724-8569
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Colorado Anschutz Medical Campus | Aurora | Colorado | 80045 | Maria Rodriguez, BA 303-724-0738 |
Find similar trials in Aurora, CO
By research site
Related Studies
- An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)PHASE2 · Recruiting · Avalyn Pharma Inc. · Birmingham, Alabama
- A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary FibrosisPHASE2 · Recruiting · Rein Therapeutics · Birmingham, Alabama
- A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.PHASE2 · Not Yet Recruiting · AstraZeneca · Birmingham, Alabama
- Collection of Airway, Blood and/or Urine Specimens From Subjects for Research StudiesRecruiting · Weill Medical College of Cornell University · New York, New York